Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 17/20 | 0.75 |
| ▸ | THRA | P10827 | 16/20 | 0.75 |
| ▸ | EGLN1 | Q9GZT9 | 6/20 | 0.75 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.74 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.74 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.74 |
| ▸ | ASPH | Q12797 | 1/20 | 0.74 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.74 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5140997 | 0.92 | THRB (0.80) | THRBTHRAEGLN1BBOX1SLC6A2 | |
| SCHEMBL969046 | 0.86 | THRA (0.86) | THRBTHRAEGLN1BBOX1SLC6A2 | |
| SCHEMBL22168443 | 0.86 | THRA (0.80) | THRBTHRAEGLN1BBOX1SLC6A2 | |
| SCHEMBL522940 | 0.86 | THRA (1.00) | THRBTHRAEGLN1BBOX1SLC6A2 | |
| SCHEMBL523415 | 0.85 | THRA (0.74) | THRBTHRAEGLN1BBOX1SLC6A2 | |
| SCHEMBL27434315 | 0.85 | THRB (1.00) | THRBTHRAEGLN1BBOX1SLC6A2 | |
| SCHEMBL31028967 | 0.85 | THRA (1.00) | THRBTHRAEGLN1BBOX1SLC6A2 | |
| Roxadustat SCHEMBL29350689 | 0.85 | THRA (1.00) | THRBTHRAEGLN1BBOX1SLC6A2 | |
| Roxadustat SCHEMBL523705 | 0.85 | THRA (1.00) | THRBTHRAEGLN1BBOX1SLC6A2 | |
| Roxadustat SCHEMBL29892426 | 0.85 | THRA (1.00) | THRBTHRAEGLN1BBOX1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100331362-A1 | Treatment method for anemia | FIBROGEN, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20060276477-A1 | Treatment method for anemia | FIBROGEN, INC. (US) | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331362-A1 | Treatment method for anemia | THPO, EPOR, MPL | THRB 574/4885THRA 247/4885EGLN1 85/4885 |
| US-20060276477-A1 | Treatment method for anemia | THPO, EPOR, MPL | THRB 574/4885THRA 247/4885EGLN1 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.